Jefferies Financial Group Inc. Invests $753,000 in Evolus, Inc. (NASDAQ:EOLS)

Jefferies Financial Group Inc. purchased a new position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 68,181 shares of the company's stock, valued at approximately $753,000. Jefferies Financial Group Inc. owned 0.11% of Evolus as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its holdings in Evolus by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after buying an additional 1,291 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Evolus by 2.2% in the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock worth $885,000 after acquiring an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC raised its holdings in shares of Evolus by 18.2% in the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares during the last quarter. MetLife Investment Management LLC lifted its position in Evolus by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock valued at $378,000 after acquiring an additional 2,044 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Evolus by 19.5% during the 4th quarter. Teacher Retirement System of Texas now owns 14,084 shares of the company's stock valued at $155,000 after purchasing an additional 2,302 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on EOLS. BTIG Research initiated coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective for the company. Barclays boosted their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $23.75.

Insider Activity

In other news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the sale, the chief marketing officer now directly owns 95,671 shares of the company's stock, valued at approximately $1,268,597.46. This represents a 4.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Moatazedi sold 6,251 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares in the company, valued at $6,306,875.60. This represents a 1.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,241 shares of company stock valued at $1,048,666 over the last quarter. Company insiders own 5.90% of the company's stock.

Evolus Stock Performance

Evolus stock traded up $0.20 during midday trading on Monday, reaching $9.90. The stock had a trading volume of 1,139,162 shares, compared to its average volume of 687,728. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $638.31 million, a PE ratio of -10.88 and a beta of 1.11. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The firm's 50-day moving average price is $11.32 and its 200 day moving average price is $12.31.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.